DelveInsight's Hereditary Transthyretin Amyloidosis Market Insights report includes a comprehensive understanding of current treatment practices, hereditary transthyretin amyloidosis emerging drugs, ...
Based on Nobel Prize-winning CRISPR/Cas9 gene editing technology, nex-z has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis. Nex-z is designed to inactivate ...
A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...
Based on Nobel Prize-winning CRISPR/Cas9 technology, nex-z has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis. Nex-z is designed to inactivate the TTR gene ...
It elucidates the series of events involving the dissociation, misfolding and aggregation of TTR proteins, resulting in the formation of amyloid fibrils. It also higlights various therapeutic ...
University College London's National Amyloidosis Center leads a multinational team reporting that a single infusion of an in vivo gene-editing therapy (nexiguran ziclumeran) produced rapid, deep, and ...
Here is our Top Docs 2025 profile on Jeffrey Zonder, M.D., who is part of the Karmanos Cancer Institute’s Multiple Myeloma ...
The hereditary transthyretin amyloidosis market is experiencing significant growth driven by increasing disease awareness, advancements in gene-silencing therapies, and the rising ...
CAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback